Philip Nofal, MD
Psychiatry · Concord, NCNPI 1932139458
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 57.3% of the total. Reporting peaked in 2020 at $3,354 and has fallen 96.0% since, to $135 in 2025.
Across 94 payments — averaging $59.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Neuronetics, Inc.$829
- AbbVie$424
- Otsuka America Pharmaceutical, Inc.$333
- Johnson & Johnson$263
- Indivior Inc.$108
- plus $431 from 9 others
What the payments were for
- Consulting fees$3,08055%
- Travel & lodging$80514%
- Food & beverage$1,70030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $3,198 |
| Neuronetics, Inc. | 2 | $829 |
| AbbVie(2 entities) | 27 | $424 |
| Otsuka America Pharmaceutical, Inc. | 15 | $333 |
| Johnson & Johnson | 14 | $263 |
| Indivior Inc. | 5 | $108 |
| Alkermes, Inc. | 5 | $97 |
| Vanda Pharmaceuticals Inc. | 5 | $87 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
| MDD US Operations, LLC | 2 | $25 |
| Corium, LLC | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,585 in reported general payments places this provider in the 85th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 41 | $2,626 |
| Risperidone | 11 | $279 |
| Sertraline Hcl | 15 | $197 |
| Fluoxetine Hcl | 15 | $28 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Concord
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
- David JoyeAlbemarle$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.